Waverley Pharma (WAVE) Financial Statements

5 Followers

Waverley Pharma Financial Overview

Waverley Pharma's market cap is currently C$810.00K. The company's EPS TTM is C$; its P/E ratio is -1.29; Waverley Pharma is scheduled to report earnings on August 20, 2026, and the estimated EPS forecast is C$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue
Gross Profit	$ 79.80K	$ 581.78K	$ 222.67K	$ 181.71K	$ 48.94K
Operating Income	$ -2.23M	$ -638.16K	$ -786.83K	$ -709.60K	$ -1.41M
EBITDA	$ -1.72M	$ -435.33K	$ -726.25K	-	-
Net Income	$ -2.22M	$ -664.08K	$ -796.51K	$ -705.76K	$ -1.21M
Balance Sheet
Cash & Short-Term Investments	$ ―	$ ―	$ ―	$ ―	$ ―
Total Assets	$ 952.29K	$ 2.69M	$ 3.68M	$ 3.49M	$ 4.39M
Total Debt	$ 1.60M	$ 701.73K	$ 262.36K	$ 40.00K	$ 0.00
Net Debt	$ 1.55M	$ 567.93K	$ 104.24K	$ -670.49K	$ -1.48M
Total Liabilities	$ 2.09M	$ 1.60M	$ 1.89M	$ 1.45M	$ 1.55M
Stockholders' Equity	$ ―	$ ―	$ ―	$ ―	$ ―
Cash Flow
Free Cash Flow	$ -1.02M	$ -237.06K	$ -798.78K	$ -361.70K	$ -1.41M
Operating Cash Flow	$ -1.02M	$ -237.06K	$ -798.78K	$ -361.70K	$ -1.41M
Investing Cash Flow
Financing Cash Flow

Waverley Pharma Earnings and Revenue History

Income Statement >

Waverley Pharma Debt to Assets

Balance Sheet >

Waverley Pharma Cash Flow

Cash Flow >

Waverley Pharma Forecast EPS vs Actual EPS

Earnings >